In March 2015, Vanda announced positive results from a Phase II proof of concept study.

[3] A proof of concept study is done in early stage clinical trials after there have been promising preclinical results.

In a 12-week randomized trial of LY68017 in 189 patients with social anxiety disorder, 50 mg of LY68017 did not provide any statistically significant improvement over placebo.

[6] Tradipitant underwent phase II clinical trials assessing its utility in the treatment of gastroparesis the results of which were announced on December 3, 2018.

It also showed a statistically significant improvement in nausea-free days, and key gastroparesis scales.